glp-1 drops dosage for weight loss Subscription Lemme Reset™ GLP-1 Production Support

Description

Effects of SGLT2 Inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes

Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study

Funding This work was supported by: Institutional grants from the University of Padova

A Type II variation application has been submitted to the European Medicines Agency (EMA) seeking the approval of teclistamab (Tecvayli) monotherapy for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.1 The application is supported by data from the phase 3 MajesTEC-9 trial (NCT05572515), which showed that teclistamab reduced the risk of disease progression or death by 71% compared with standard-of-care (SOC) therapy (HR, 0.29